- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02022761
Safety, Tolerability and Pharmacokinetics of Inhaled Laninamivir Octanoate TwinCaps® DPI in Adults With Chronic Asthma
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Inhaled Laninamivir Octanoate in Adults With Chronic Asthma
Study Overview
Detailed Description
32 subjects, as two sequential groups of 16 subjects at each dose level (40 mg and 80 mg), will be randomised 3:1 to receive active drug or matching placebo.
Males and females aged 18 to 65 years inclusive, with mild or moderate chronic asthma.
Stratum 1: Mild asthma - requiring treatment consistent with Global Initiative for Asthma (GINA) Step 2 Stratum 2: Moderate asthma - requiring treatment consistent with GINA Step 3
Following a screening period of up to 30 days, eligible consenting subjects will be admitted to the clinic on the morning of Day 1. Laninamivir octanoate will be administered on Day 1. Subjects will remain in the clinic until Day 3 and will return for subsequent outpatient visits on Day 5, Day 6 and Day 7. A final follow-up visit for safety evaluations will occur on Day 14 ± 1 (or at the time of premature discontinuation). Each subject will participate in the study for approximately 7 weeks.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, W1G 8HU
- Respiratory Clinical Trials
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male or female subjects 18 to 65 years of age, inclusive
- Body mass index (BMI) within the range of 19.0 to 33.0 kg/m2, inclusive at screening
- Minimum weight of 55.0 kg at screening and pre-dose Day 1
- Clinical diagnosis of asthma by a physician for ≥12 months prior to screening confirmed in writing and/or by medical records
- Mild asthmatics currently requiring treatment with low dose inhaled corticosteroids or other low intensity treatment OR Moderate asthmatics, requiring treatment with low dose inhaled corticosteroids and long-acting beta agonists, medium- high dose inhaled corticosteroids alone or low dose inhaled corticosteroids and other low intensity treatment8
Well controlled asthma for 1 month prior to dosing defined by the following:
- Daytime symptoms occur ≤8 times/ 4 weeks
- Daily activity is not limited by asthma
- No nocturnal symptoms resulting in nighttime awakenings
- Use of short-acting beta-agonist (SABA) ≤8 times/4 weeks for the treatment of symptoms
- There has been no change in asthma medication (dose or regimen) within 4 weeks prior to dosing
- Pre-short-acting β2 agonist (SABA) forced expiratory volume in 1 second (FEV1) of ≥80% of predicted normal values at screening
- Non-smokers for at least 6 months prior to screening and agrees not to smoke during the study
- Negative test results for smoking status at screening (urine cotinine) and pre-dose Day 1 (Smokerlyser)
- Female subjects of childbearing potential must be practising true abstinence when this is in line with the preferred and usual lifestyle of the subject (Periodic abstinence, e.g. calendar, ovulation, symptothermal, post-ovulation methods and withdrawal are not acceptable methods of contraception), or be using and willing to continue using a medically acceptable form of birth control for at least 1 month prior to screening (at least 3 months for hormonal contraceptives) and for at least 1 month after the last study drug administration
- Male subjects of reproductive potential who are not truly abstinent must be using and willing to continue using medically acceptable contraceptive precautions from screening and for at least 1 month after the last study drug administration
- Female subjects must have a negative serum pregnancy test at screening and a negative urine pregnancy test pre-dose Day 1
- Able to speak, read, and understand English sufficiently to understand the nature of the study, to provide informed consent, and to allow completion of all study assessments
- Must provide written informed consent prior to the initiation of any protocol-specific procedures
Exclusion Criteria:
- A history of a life-threatening asthma exacerbation that required intubation and mechanical ventilation
- History of severe asthma exacerbation in the last year that required the use of systemic corticosteroids (tablets, suspension or injection)
- Hospitalization or a visit to ER because of asthma in the last year
- Intensive care admission for asthma in the previous 5 years
- Any clinically significant abnormalities on clinical chemistry, haematology, or urinalysis, as judged by the investigator (at screening and/or Day -1)
- Clinically significant abnormalities on physical examination, medical history, 12-lead ECG, or vital signs, as judged by the investigator (at screening or pre-dose Day 1)
- A QTcF >430 msec for male subjects and >450 msec for female subjects on ECG at screening or pre-dose Day 1
- History or presence of any clinically significant illness (e.g., cardiovascular, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, musculoskeletal, or psychiatric) or any other condition, which in the opinion of the investigator would jeopardize the safety of the subject or the validity of the study results
- History or clinical evidence of other respiratory disease (e.g., COPD, cystic fibrosis)
- Recent (within 2 weeks) or current signs or symptoms of a respiratory infection at screening or pre-dose Day 1
- Currently taking theophylline or has taken theophylline in the 3 months prior to screening
- Use of non-prescription drugs within 3 days prior to Day 1
- Use of prescription medications (except acceptable asthma medications, acceptable forms of birth control, and hormone replacement) and recreational drugs within 14 days prior to Day 1
- Positive urine drug screen or breath alcohol test at screening or pre-dose Day 1
- Female subjects who are pregnant or lactating or who are planning to become pregnant within 30 days of study drug administration
- History of allergy, hypersensitivity, or serious adverse reaction to lactose or neuraminidase inhibitors
- Previous exposure to laninamivir octanoate
- Positive for Hepatitis B surface antigen, Hepatitis C virus antibody, or Human Immunodeficiency Virus (HIV) p24 antigen/antibodies at screening
- Donation or loss of ≥500 mL whole blood within 2 months prior to Day 1
- Current or pending legal charges or currently on probation, based on subject report
- Receipt of an investigational product in a clinical trial within 30 days or 5 half-lives, whichever is longer, prior to Day 1
- Concurrent enrolment in any other type of medical research, judged by the investigator not to be scientifically or medically compatible with this study
- An employee of the sponsor or research site personnel directly affiliated with this study or their immediate family members defined as a spouse, parent, sibling, or child, whether biological or legally adopted
- A subject who, in the opinion of the investigator, is not considered to be suitable and is unlikely to comply with the study protocol for any reason
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 40 mg Laninamivir octanoate
Dry Powder Inhaler
|
40 mg dose consists of 2 laninamivir octanoate TwinCaps® DPI 80 mg dose consists of 4 laninamivir octanoate TwinCaps® DPI (2 administered 12 hours apart)
Other Names:
|
Experimental: 80 mg Laninamivir octanoate
Dry Powder Inhaler
|
40 mg dose consists of 2 laninamivir octanoate TwinCaps® DPI 80 mg dose consists of 4 laninamivir octanoate TwinCaps® DPI (2 administered 12 hours apart)
Other Names:
|
Placebo Comparator: Matching placebo
Dry Powder Inhaler
|
40 mg dose consists of 2 laninamivir octanoate TwinCaps® DPI 80 mg dose consists of 4 laninamivir octanoate TwinCaps® DPI (2 administered 12 hours apart)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the safety and tolerability of single ascending doses (40 mg and 80 mg) of laninamivir octanoate administered by inhalation via the TwinCaps® DPI in adults with mild or moderate chronic asthma.
Time Frame: Subjects assessed at clinic visits and up to 14 days post-dose
|
Safety and tolerability data will be presented according to the dose group and asthma Strata.
All safety data will be summarized with descriptive statistics and included assessments of SAEs, AEs, Laboratory Results, Vital Signs, ECGs, Spirometry parameters, Con Meds, Physical Exam findings
|
Subjects assessed at clinic visits and up to 14 days post-dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the pharmacokinetics of laninamivir octanoate and its active metabolite laninamivir following administration of 40 mg & 80 mg doses of laninamivir octanoate by inhalation via the TwinCaps® DPI in adults with mild or moderate chronic a
Time Frame: Samples are collected up to 144 hours post-dose
|
Cohort 1 - Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 96, 120 and 144 hours post dose Cohort 2 - Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 15, 16, 18, 20, 24, 36, 48, 96, 120 and 144 hours post dose Pharmacokinetic concentration data and PK parameters will be calculated and summarized. |
Samples are collected up to 144 hours post-dose
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Jolanta Airey, Dr, Biota Scientific Management Pty Ltd
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BTA51-350-101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on Laninamivir octanoate
-
Biota Scientific Management Pty LtdDepartment of Health and Human ServicesTerminated
-
Biota Scientific Management Pty LtdDepartment of Health and Human ServicesCompletedInfluenzaUnited States, Peru, Hungary, Canada, South Africa, Estonia, Australia, Belgium, Bulgaria, Colombia, France, Germany, Latvia, Mexico, New Zealand, United Kingdom
-
Virginia Commonwealth UniversityMeridian Bioscience, Inc.TerminatedMetabolic Syndrome | Nonalcoholic Fatty Liver DiseaseUnited States
-
Université de SherbrookeCompleted
-
Universitaire Ziekenhuizen KU LeuvenCompletedHealthy | Gastric EmptyingBelgium
-
Meridian Bioscience, Inc.Medical University of South Carolina; Northwestern University; Hadassah Medical... and other collaboratorsTerminatedHepatocellular Carcinoma (HCC) | Chronic Liver DiseaseCanada
-
Beijing 302 HospitalUnknown
-
Meridian Bioscience, Inc.CompletedNon-Alcoholic SteatohepatitisUnited States, France, Belgium, United Kingdom
-
Hadassah Medical OrganizationMeridian Bioscience, Inc.Unknown
-
Biota Scientific Management Pty LtdNational Institute of Allergy and Infectious Diseases (NIAID)CompletedInfluenzaUnited Kingdom